The quest to overcome resistance to EGFR-targeted therapies in cancer

被引：0

作者：

Curtis R Chong

Pasi A Jänne

机构：

[1] Lowe Center for Thoracic Oncology,Department of Medicine

[2] Dana-Farber Cancer Institute,undefined

[3] Brigham and Women's Hospital,undefined

[4] Belfer Institute for Applied Cancer Science,undefined

[5] Dana-Farber Cancer Institute,undefined

来源：

Nature Medicine | 2013年 / 19卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Despite the initial promise of cancer therapies targeted against the epidermal growth factor receptor (EGFR), tumors treated with these agents eventually develop resistance. In this Review, the authors outline the complex mechanisms by which tumors become resistant to EGFR-targeted drugs and antibodies and offer insights into new strategies that might be employed to circumvent therapeutic resistance.

引用

页码：1389 / 1400

页数：11

共 50 条

[41] Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer
Zhang, Zhenfeng
Lee, Jae Cheol
Lin, Luping
Olivas, Victor
Au, Valerie
LaFramboise, Thomas
Abdel-Rahman, Mohamed
Wang, Xiaoqi
Levine, Alan D.
Rho, Jin Kyung
Choi, Yun Jung
Choi, Chang-Min
Kim, Sang-We
Jang, Se Jin
Park, Young Soo
Kim, Woo Sung
Lee, Dae Ho
Lee, Jung-Shin
Miller, Vincent A.
Arcila, Maria
Ladanyi, Marc
Moonsamy, Philicia
Sawyers, Charles
Boggon, Titus J.
Ma, Patrick C.
Costa, Carlota
Taron, Miquel
Rosell, Rafael
Halmos, Balazs
Bivona, Trever G.
NATURE GENETICS, 2012, 44 (08) : 852 - +
[42] Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer
Zhenfeng Zhang
Jae Cheol Lee
Luping Lin
Victor Olivas
Valerie Au
Thomas LaFramboise
Mohamed Abdel-Rahman
Xiaoqi Wang
Alan D Levine
Jin Kyung Rho
Yun Jung Choi
Chang-Min Choi
Sang-We Kim
Se Jin Jang
Young Soo Park
Woo Sung Kim
Dae Ho Lee
Jung-Shin Lee
Vincent A Miller
Maria Arcila
Marc Ladanyi
Philicia Moonsamy
Charles Sawyers
Titus J Boggon
Patrick C Ma
Carlota Costa
Miquel Taron
Rafael Rosell
Balazs Halmos
Trever G Bivona
Nature Genetics, 2012, 44 : 852 - 860
[43] Mechanisms of resistance to egfr-targeted therapy induced by nicotine in human lung cancer
Extremera Mazuela, Maria
Bordas Sanchez, Anna
Montiel Lopez, Carmen
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2019, 125 : 30 - 30
[44] Trials to overcome drug resistance to EGFR and ALK targeted therapies past, present, and future
Spaans, Johanna N.
Goss, Glenwood D.
FRONTIERS IN ONCOLOGY, 2014, 4
[45] Rational combination of targeted therapies as a strategy to overcome the mechanisms of resistance to inhibitors of EGFR signaling
Bianco, Roberto
Damiano, Vincenzo
Gelardi, Teresa
Daniele, Gennaro
Ciardiello, Fortunato
Tortora, Giampaolo
CURRENT PHARMACEUTICAL DESIGN, 2007, 13 (33) : 3358 - 3367
[46] Inflammatory signaling in targeted therapy resistance: focus on EGFR-targeted treatment
Luo, Zhihong
Gong, Ke
CANCER BIOLOGY & MEDICINE, 2024, 21 (10) : 831 - 837
[47] Inflammatory signaling in targeted therapy resistance: focus on EGFR-targeted treatment
Zhihong Luo
Ke Gong
Cancer Biology & Medicine, 2024, 21 (10) : 831 - 837
[48] EGFR-targeted therapy
Vecchione, Loredana
Jacob, Bart
Normanno, Nicola
Ciardiello, Fortunato
Tejpar, Sabine
EXPERIMENTAL CELL RESEARCH, 2011, 317 (19) : 2765 - 2771
[49] Fibronectin-mediated activation of Stat3 facilitates the resistance of triple negative breast cancer to EGFR-targeted therapies
Wendt, Michael K.
Balanis, Nikolas
Carlin, Cathleen
Schiemann, William
CLINICAL CANCER RESEARCH, 2012, 18 (10)
[50] Advances in erlotinib delivery systems: Addressing challenges and exploring opportunities in EGFR-targeted cancer therapies
Pourmadadi, Mehrab
Mohammadzadeh, Vahideh
Mohammadi, Zahra Sadat
Poorkhalili, Pegah
Afjoul, Neda
Behzadmehr, Razieh
Fathi-Karkan, Sonia
Rahdar, Abbas
Ghotekar, Suresh
INORGANIC CHEMISTRY COMMUNICATIONS, 2024, 161

← 1 2 3 4 5 →